Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 11/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338323 | 0.98 | PLA2G2A (0.48) | PLA2G2ALMNAALDH1A1MAPTBRD4 | |
| SCHEMBL6337925 | 0.88 | PLA2G2A (0.49) | PLA2G2ALMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6332702 | 0.86 | PLA2G2A (0.39) | PLA2G2ALMNAALDH1A1MAPTTSHR | |
| SCHEMBL6339344 | 0.85 | PLA2G2A (0.46) | PLA2G2AP2RX7FABP4 | |
| SCHEMBL6341055 | 0.84 | PLA2G2A (0.66) | PLA2G2ALMNAALDH1A1MAPTRAB9A | |
| SCHEMBL6333151 | 0.84 | PLA2G2A (0.50) | PLA2G2AFABP4 | |
| SCHEMBL6333100 | 0.84 | PLA2G2A (0.48) | PLA2G2AP2RX7FABP4 | |
| SCHEMBL6335034 | 0.83 | PLA2G2A (0.48) | PLA2G2ABRD4P2RX7FABP4 | |
| SCHEMBL6333107 | 0.83 | PLA2G2A (0.45) | PLA2G2ABRD4FABP4 | |
| SCHEMBL6333036 | 0.83 | PLA2G2A (0.49) | PLA2G2AFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974831-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040077704-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077704-A1 | Novel spla2 inhibitors | PLAAT2, PLA2G12A, PLA2G4A | PLA2G2A 19/4885LMNA 3752/4885ALDH1A1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.